---
title: "한미약품에 대해 투자의견 BUY, 목표주가 72만원(상향)을 제시했다. — 하나증권 — DecisionGateway"
description: "prediction by 하나증권, recorded recently — verbatim quote and source citation."
canonical_url: "https://dgw.tmarket.io/claims/01a1ceb7-cec9-757b-bb0f-1e5b020a6c9a"
meta:
  "og:description": "prediction by 하나증권, recorded recently — verbatim quote and source citation."
  "og:image": "https://dgw.tmarket.io/og.jpg"
  "og:image:alt": "White network of connected nodes crossed by a timeline on black"
  "og:image:height": "1024"
  "og:image:width": "1024"
  "og:title": "한미약품에 대해 투자의견 BUY, 목표주가 72만원(상향)을 제시했다. — 하나증권 — DecisionGateway"
  "twitter:image": "https://dgw.tmarket.io/og.jpg"
---

> Index of every page on this site: [llms.txt](https://dgw.tmarket.io/llms.txt)

prediction

# **한미약품에 대해 투자의견 BUY, 목표주가 72만원(상향)을 제시했다.**

A prediction by [**하나증권**](https://dgw.tmarket.io/actors/01a1cea2-176c-7cf2-87ea-9ed64a8130ca). Statements are as reported by the cited publishers — not verified by DecisionGateway.

> *투자의견 BUY (괴리율 54.2%) 목표주가: 72만원 (상향)*

hanaresearchPublished 2026-11-08 [ Read source](https://t.me/hanaresearch/20910)

[**하나증권 dossier **](https://dgw.tmarket.io/actors/01a1cea2-176c-7cf2-87ea-9ed64a8130ca)

## **Related claims**

[**목표주가를 18만원에서 16만원으로 하향 조정하고 투자의견 '매수'를 유지한다.**하나증권 · commitment](https://dgw.tmarket.io/claims/01a1cea4-e6d9-7273-a762-a0d8e5bdf274) [**HanAll Biopharma is forecast to post 2027 revenue of 177.3 billion KRW, operating profit of 10.6 billion KRW, and an operating margin of 6.0%.**report author · prediction](https://dgw.tmarket.io/claims/01a1d4b6-f723-73df-9e13-66f79ab9d480) [**MANKIND PHARMA technical pick: Buy with target 2790, potential upside \~8%.**Motilal Oswal · prediction](https://dgw.tmarket.io/claims/01a1cf98-d5e3-7487-aa99-1bb7813eaf93) [**실적 추정치와 적정 밸류에이션(12MF PER 8배->7배)을 하향 조정해 목표주가를 43만원에서 36.5만원으로 하향했다.**하나증권 · commitment](https://dgw.tmarket.io/claims/01a1ceb6-59b7-7505-80d2-b535a5d76df7) [**HanAll Biopharma is forecast to post 2026 revenue of 169.3 billion KRW, operating profit of 12.0 billion KRW, and an operating margin of 7.1%.**report author · prediction](https://dgw.tmarket.io/claims/01a1d4b6-f715-7150-a782-62a08f93decd) [**삼미금속의 '26년 예상 실적은 매출 811억원(YoY+10.0%), 영업이익 86억원(YoY+48.0%, OPM 10.6%)이고, '27년 매출액은 1,000억원 이상의 성장을 기록할 전망이다.**하나증권 미래산업팀 · prediction](https://dgw.tmarket.io/claims/01a1cea9-f54f-7c9b-9914-b5ca86008567)

## **More claims by 하나증권**

[**The report reviewed trends and major economic indicators in the U.S. and Chinese stock markets and analyzed valuations and trends by global sector.**statement](https://dgw.tmarket.io/claims/01a1d4ae-b231-7d52-805c-3f604b6a5af0) [**The U.S. should watch AI-related regulation and volatility in the semiconductor sector, while for China domestic demand stimulus and policy effects will be key to a sustained rebound.**statement](https://dgw.tmarket.io/claims/01a1d4ae-b21a-7518-829b-60cdc773571a) [**This report is a weekly report covering global sector trends and indicators rather than a single earnings estimate for an individual company, and it does not provide annual aggregate earnings figures.**statement](https://dgw.tmarket.io/claims/01a1d4ae-b20e-78ef-8998-71366dda0c35) [**An approach centered on core theme ETFs such as generative AI, semiconductors, quality and cybersecurity, and on major big tech stocks, remains valid.**statement](https://dgw.tmarket.io/claims/01a1d4ae-b203-77a2-bb21-b5002bb38a65) [**Ahead of Nvidia's earnings release on 11/18, market attention is focused on Blackwell demand and next-generation GPU supply outlook.**statement](https://dgw.tmarket.io/claims/01a1d4ae-b1f8-780c-a428-efe4735941fd)

[All claims by 하나증권](https://dgw.tmarket.io/claims?claimant_id=01a1cea2-176c-7cf2-87ea-9ed64a8130ca)

[All claims](https://dgw.tmarket.io/claims)

```json
{"@context":"https://schema.org","@graph":[{"@id":"https://dgw.tmarket.io/#website","@type":"WebSite","description":"Decisions, events and falsifiable forecasts from 3,800+ Telegram channels — every claim cited. Read free.","name":"DecisionGateway","url":"https://dgw.tmarket.io/","publisher":{"@id":"https://dgw.tmarket.io/#identity"}},{"@id":"https://dgw.tmarket.io/claims/01a1ceb7-cec9-757b-bb0f-1e5b020a6c9a#webpage","@type":"WebPage","description":"prediction by 하나증권, recorded recently — verbatim quote and source citation.","name":"한미약품에 대해 투자의견 BUY, 목표주가 72만원(상향)을 제시했다. — 하나증권 — DecisionGateway","url":"https://dgw.tmarket.io/claims/01a1ceb7-cec9-757b-bb0f-1e5b020a6c9a","breadcrumb":{"@id":"https://dgw.tmarket.io/claims/01a1ceb7-cec9-757b-bb0f-1e5b020a6c9a#breadcrumb"},"isPartOf":{"@id":"https://dgw.tmarket.io/#website"},"potentialAction":[{"@type":"ReadAction","target":["https://dgw.tmarket.io/claims/01a1ceb7-cec9-757b-bb0f-1e5b020a6c9a"]}]},{"@id":"https://dgw.tmarket.io/#identity","@type":"Organization","name":"DecisionGateway","url":"https://dgw.tmarket.io"},{"@id":"https://dgw.tmarket.io/claims/01a1ceb7-cec9-757b-bb0f-1e5b020a6c9a#breadcrumb","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","name":"Home","item":"https://dgw.tmarket.io","position":1},{"@type":"ListItem","name":"Claims","item":"https://dgw.tmarket.io/claims","position":2},{"@type":"ListItem","name":"한미약품에 대해 투자의견 BUY, 목표주가 72만원(상향)을 제시했다.","position":3}]},{"@id":"https://dgw.tmarket.io/claims/01a1ceb7-cec9-757b-bb0f-1e5b020a6c9a#/schema/quotation/1","@type":"Quotation","dateCreated":"2026-11-08","isBasedOn":"https://t.me/hanaresearch/20910","text":"투자의견 BUY (괴리율 54.2%)\n목표주가: 72만원 (상향)","url":"/claims/01a1ceb7-cec9-757b-bb0f-1e5b020a6c9a","spokenByCharacter":{"@type":"Person","name":"하나증권","@id":"/actors/01a1cea2-176c-7cf2-87ea-9ed64a8130ca"}}]}
```

## Sitemap

See the full [sitemap](https://dgw.tmarket.io/sitemap.md) for all pages.